NSCLC STAGE IV

This early-phase study tests a peptide vaccine designed to train the immune system to attack ALK-positive lung cancer cells. The goal is to prevent or delay resistance to standard targeted therapies. About 12 adults with advanced ALK+ non-small cell lung cancer who are stable on …

This study tests whether adding pirfenidone to the immunotherapy drug atezolizumab can help shrink tumors and overcome treatment resistance in people with stage 4 or recurrent non-small cell lung cancer. About 25 adults who have already had at least one prior treatment will recei…

This study tests whether combining a hormone therapy (leuprorelin) with an immunotherapy drug (sintilimab) can help control advanced lung cancer in men aged 60 and older. The goal is to see if the hormone treatment boosts the immune system to make the immunotherapy work better. A…

This study tests whether adding a precise, high-dose radiation treatment to the liver (L-SABR) to standard immunotherapy can help people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will be randomly assigned to receive either standard dru…

This study tests a new drug called M701 in 96 adults with advanced lung cancer that has spread and caused fluid buildup around the lungs (malignant pleural effusion). The drug is a special antibody designed to help the immune system attack cancer cells. The main goals are to chec…

This study tests a combination of two drugs (Sacituzumab Tirumotecan and Furmonertinib) in 25 adults with advanced non-squamous non-small cell lung cancer that has an EGFR gene mutation and has worsened after standard treatments. The goal is to see if the combo can shrink tumors …

This study looks at how well the immunotherapy drug atezolizumab works as the first treatment for people with stage IV non-small cell lung cancer that has high levels of a protein called PD-L1 and no targetable gene changes. Researchers will track survival, tumor response, and si…

This study tests a new drug called repotrectinib in 30 frail or elderly patients with advanced lung cancer that has a specific genetic change (ROS1). The goal is to see if the drug can shrink tumors and be well-tolerated in this group, who are often left out of other trials. Part…

This phase 3 trial tests whether adding the experimental drug N-803 to standard chemotherapy (docetaxel) and another immunotherapy (tislelizumab) helps people with advanced non-small cell lung cancer whose cancer has stopped responding to prior immunotherapy. About 507 participan…

This study tests whether continuing the immunotherapy drug cemiplimab for up to a year can help people with stage IV non-small cell lung cancer that has spread to only a few spots (oligometastatic). After initial treatment with cemiplimab plus chemotherapy and targeted radiation …